Literature DB >> 14564314

Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis.

Jamieson Macdonald Bourque1, Vic Hasselblad, Eric J Velazquez, Salvador Borges-Neto, Christopher M O'connor.   

Abstract

BACKGROUND: The effects of viability status and treatment allocation on long-term mortality in patients with left ventricular dysfunction and coronary artery disease have not been determined. Several observational studies with significant limitations have addressed this issue, and a recent meta-analysis has attempted to combine these results to increase statistical power. However, the analysis did not test for an interaction between viability status and treatment type, and included extraneous studies. We provide an alternate meta-analysis of this primary literature, utilizing interaction statistical methodology on relevant data and factoring in multiple limitations.
METHODS: We examined papers from this prior meta-analysis examining viable and nonviable patients undergoing surgical or medical therapy. We determined an interaction odds ratio for each study and used an empirical Bayes random-effects model to obtain a combined interaction odds ratio that was tested for statistical significance. We compared our results against an interaction odds ratio we estimated from the primary studies included in the previous meta-analysis.
RESULTS: Nine relevant studies with 1244 patients and 172 events were identified that utilized all 4 treatment/viability subsets. The interaction odds ratio was 2.76 (P =.0176, 95% CI 1.19-6.38), 2.5 times lower than our estimated interaction odds ratio of 7.27 for the prior meta-analysis.
CONCLUSIONS: We found a markedly reduced but statistically significant interaction between viability status and treatment allocation. However, numerous limitations in the primary studies and the application of meta-analysis along with significant improvements in medical therapies render a randomized controlled trial necessary to reach a definitive conclusion to this critical question.

Entities:  

Mesh:

Year:  2003        PMID: 14564314     DOI: 10.1016/S0002-8703(03)00428-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  To revascularize or not to revascularize: a dilemma in heart failure.

Authors:  Roxy Senior
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

2.  Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium.

Authors:  V Rizzello; D Poldermans; E Biagini; A F L Schinkel; R van Domburg; A Elhendy; E C Vourvouri; M Bountioukos; A Lombardo; B Krenning; J R T C Roelandt; J J Bax
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

Review 3.  Is ischemia the most powerful indicator of myocardial viability?

Authors:  Jamshid Shirani
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

Review 4.  Diagnostic and imaging considerations: role of viability.

Authors:  Roxy Senior
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

5.  Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from coronary revascularization.

Authors:  Eric J Velazquez
Journal:  Circ Cardiovasc Imaging       Date:  2012-03       Impact factor: 7.792

Review 6.  Heart failure.

Authors:  Robert Samuel McKelvie
Journal:  BMJ Clin Evid       Date:  2011-08-30

7.  Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings.

Authors:  Jamieson M Bourque; Eric J Velazquez; Robert H Tuttle; Linda K Shaw; Christopher M O'Connor; Salvador Borges-Neto
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

Review 8.  Imaging the myocardial ischemic cascade.

Authors:  Arthur E Stillman; Matthijs Oudkerk; David A Bluemke; Menko Jan de Boer; Jens Bremerich; Ernest V Garcia; Matthias Gutberlet; Pim van der Harst; W Gregory Hundley; Michael Jerosch-Herold; Dirkjan Kuijpers; Raymond Y Kwong; Eike Nagel; Stamatios Lerakis; John Oshinski; Jean-François Paul; Riemer H J A Slart; Vinod Thourani; Rozemarijn Vliegenthart; Bernd J Wintersperger
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-19       Impact factor: 2.357

Review 9.  Noninvasive assessment myocardial viability: current status and future directions.

Authors:  Kevin C Allman
Journal:  J Nucl Cardiol       Date:  2013-06-15       Impact factor: 5.952

10.  The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.

Authors:  Eric J Velazquez; Kerry L Lee; Christopher M O'Connor; Jae K Oh; Robert O Bonow; Gerald M Pohost; Arthur M Feldman; Daniel B Mark; Julio A Panza; George Sopko; Jean L Rouleau; Robert H Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.